Pure Global
NCT06389721

Understanding and Preventing Cortical Mechanisms of Chemotherapy-induced Peripheral Neuropathy

M.D. Anderson Cancer Center·ClinicalTrials.gov·diagnostic testNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Chemotherapy-induced Peripheral Neuropathy
Drug/Device/Intervention
Electroencephalogram (EEG)
Study type
Observational
Intervention type
diagnostic test
Sponsor & location
Primary sponsor
M.D. Anderson Cancer Center
Location
Houston, United States of America
Timeline & enrollment
Phase
N/A
Start date
Oct 31, 2024
End date
Jan 31, 2027
Enrollment
45 participants
Primary outcome

Safety and adverse events (AEs)

Summary

Cohort 1: To track the onset and progression of a condition called chemotherapy-induced
 peripheral neuropathy (CIPN).
 
 Cohort 2: To track the onset and progression of a condition called chemotherapy-induced
 peripheral neuropathy (CIPN) and to test a certain type of experimental neuromodulation
 (stimulation of the brain) with a device called a closed-loop brain-computer interface
 (clBCI) to see if can help to prevent pain due to CIPN.

ICD-10 classifications
Drug-induced polyneuropathyParaneoplastic neuromyopathy and neuropathyPolyneuropathy due to other toxic agentsIdiopathic peripheral autonomic neuropathyIdiopathic progressive neuropathy
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06389721
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06389721 through Pure Global AI's free database. This phase not specified trial is sponsored by M.D. Anderson Cancer Center and is currently Not yet recruiting. The study focuses on Chemotherapy-induced Peripheral Neuropathy. Target enrollment is 45 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.